Covid spike antibody test after vaccine12/19/2023 ![]() ![]() ![]() 4 Emerging data from small studies suggest that individuals who have recovered from either a recent or remote COVID-19 infection may have a sustained immunity that could be assessed via measurable antibody response to a single vaccine dose administration. 1– 3 Amidst ongoing efforts to rapidly deploy vaccinations, challenges to the supply chain have prompted queries around whether single rather than double dose administration may suffice for certain individuals – including those recovered from prior COVID-19 infection. Rapid development of vaccines against SARS-CoV-2, the causative agent of Coronavirus Disease 2019 (COVID-19), offers great promise for curbing spread of infection and accelerating the timeline towards a potential level of herd immunity. Additional studies are needed to validate our findings, which could allow for public health programs to expand the reach of population wide vaccination efforts. These results support the premise that a single dose of mRNA vaccine could provoke in COVID-19 recovered individuals a level of immunity that is comparable to that seen in infection naïve persons following a double dose regimen. Patterns were similar for the post-vaccine symptoms experienced by infection recovered persons following their first dose compared to the symptoms experienced by infection naïve persons following their second dose (P=0.66). We observed that the anti-S IgG antibody response following a single vaccine dose in persons who had recovered from confirmed prior COVID-19 infection was similar to the antibody response following two doses of vaccine in persons without prior infection (P≥0.58). For all participants, we quantified circulating levels of SARS-CoV-2 anti-spike (S) protein IgG at baseline prior to vaccine, after vaccine dose 1, and after vaccine dose 2. To this end, we examined response to Pfizer-BioNTech mRNA vaccine in a large cohort of healthcare workers including those with versus without prior COVID-19 infection. With supply chain logistics impacting the rollout of population-scale vaccination programs, increasing attention has turned to the potential efficacy of single versus double dose vaccine administration for select individuals. The double dose regimen for mRNA vaccines against SARS-CoV-2 presents both a hope and a challenge for global efforts to curb the COVID-19 pandemic. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |